Trials / Withdrawn
WithdrawnNCT02673814
Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer
An Open-Label, Randomized, Phase II Trial of Durvalumab (MEDI4736) With or Without Bavituximab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Peregrine Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to durvalumab will improve the results of the treatment for non-small-cell lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | durvalumab | |
| BIOLOGICAL | bavituximab |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2017-04-01
- Completion
- 2018-04-01
- First posted
- 2016-02-04
- Last updated
- 2016-08-01
Source: ClinicalTrials.gov record NCT02673814. Inclusion in this directory is not an endorsement.